Flagship explainer
What drives ADC Therapeutics SA’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$143M | FY2025 |
| |
| Income before tax | −$142M | FY2025 |
|
| Operating income | −$121M | FY2025 |
|
| $81.4M | FY2025 |
| |
| Ending assets | $323M | FY2025 |
|
| Beginning assets | $322M | FY2024 |
|
| −$186M | FY2025 |
| |
| −$203M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001628280-25-015131
- SEC filingFiling detailsAccession 0001628280-26-016491